ASLAN Pharmaceuticals Announces First Patient Screened in Study of Eblasakimab in Dupilumab ...
ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that it has screened the first patient in its TREK-DX study of eblasakimab in adult patients with moderate-to-severe atopic dermatitis (AD) who have previously been treated with dupilumab. Eblasakimab is a potential first-in-class monoclonal antibody targeting the IL-13 receptor that has the potential to deliver a differentiated efficacy and safety profile
By ASLAN PHARMACEUTICALS LIMITED
Published - Dec 15, 2022, 07:06 AM ET
Last Updated - Apr 29, 2024, 04:14 AM EDT